Immune-mediated therapies for liver cancer

Rajagopal N. Aravalli, Clifford J. Steer

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach for solid tumors. Its premise is based on harnessing the power of the host immune system to destroy tumor cells. Development of immune-mediated therapies, such as vaccines, adoptive transfer of autologous immune cells, and stimulation of host immunity by targeting tumor-evasive mechanisms have advanced cancer immunotherapy. In addition, studies on innate immunity and mechanisms of immune evasion have enhanced our understanding on the immunology of liver cancer. Preclinical and clinical studies with immune-mediated therapies have shown potential benefits in patients with liver cancer. In this review, we summarize current knowledge and recent developments in tumor immunology by focusing on two main primary liver cancers: hepatocellular carcinoma and cholangiocarcinoma.

Original languageEnglish (US)
Article number76
Issue number2
StatePublished - Feb 17 2017

Bibliographical note

Funding Information:
The authors acknowledge the financial support of the Institute of Engineering in Medicine, University of Minnesota, Minneapolis, MN, USA.

Publisher Copyright:
© 2017 by the authors; licensee MDPI, Basel, Switzerland.


  • Adaptive immunity
  • Adoptive cell transfer
  • Cancer vaccines
  • Cholangiocarcinoma
  • Hepatocellular carcinoma
  • Immune checkpoint blockade
  • Immunotherapy
  • Innate immunity
  • Tumor immunology


Dive into the research topics of 'Immune-mediated therapies for liver cancer'. Together they form a unique fingerprint.

Cite this